A B Ozel1, B McGee2, D Siemieniak2, P M Jacobi3, S L Haberichter3, L C Brody4, J L Mills5, A M Molloy6, D Ginsburg1,2,7,8, J Z Li1, K C Desch9. 1. Human Genetics, University of Michigan, Ann Arbor, MI, USA. 2. Howard Hughes Medical Institute, University of Michigan, Ann Arbor, MI, USA. 3. The Blood Center of Wisconsin, Milwaukee, WI, USA. 4. National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA. 5. Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA. 6. School of Medicine, Trinity College Dublin, Dublin, UK. 7. Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA. 8. Department of Pediatrics and Communicable Disease, University of Michigan, Ann Arbor, MI, USA. 9. Department of Pediatrics and Communicable Disease, University of Michigan, Ann Arbor, MI, USA. kdesch@umich.edu.
Abstract
UNLABELLED: Essentials Variants at ABO, von Willebrand Factor (VWF) and 2q12 contribute to the variation in plasma in VWF. We performed a genome-wide association study of plasma VWF propeptide in 3,238 individuals. ABO, VWF and 2q12 loci had weak or no association or linkage with plasma VWFpp levels. VWF associated variants at ABO, VWF and 2q12 loci primarily affect VWF clearance rates. SUMMARY: Background Previous studies identified common variants at the ABO and VWF loci and unknown variants in a chromosome 2q12 linkage interval that contributed to the variation in plasma von Willebrand factor (VWF) levels. Whereas the association with ABO haplotypes can be explained by differential VWF clearance, little is known about the mechanisms underlying the association with VWF single-nucleotide polymorphisms (SNPs) or with variants in the chromosome 2 linkage interval. VWF propeptide (VWFpp) and mature VWF are encoded by the VWF gene and secreted at the same rate, but have different plasma half-lives. Therefore, comparison of VWFpp and VWF association signals can be used to assess whether the variants are primarily affecting synthesis/secretion or clearance. Methods We measured plasma VWFpp levels and performed genome-wide linkage and association studies in 3238 young and healthy individuals for whom VWF levels had been analyzed previously. Results and conclusions Common variants in an intergenic region on chromosome 7q11 were associated with VWFpp levels. We found that ABO serotype-specific SNPs were associated with VWFpp levels in the same direction as for VWF, but with a much lower effect size. Neither the association at VWF nor the linkage on chromosome 2 previously reported for VWF was observed for VWFpp. Taken together, these results suggest that the major genetic factors affecting plasma VWF levels, i.e. variants at ABO, VWF and a locus on chromosome 2, operate primarily through their effects on VWF clearance.
UNLABELLED: Essentials Variants at ABO, von Willebrand Factor (VWF) and 2q12 contribute to the variation in plasma in VWF. We performed a genome-wide association study of plasma VWFpropeptide in 3,238 individuals. ABO, VWF and 2q12 loci had weak or no association or linkage with plasma VWFpp levels. VWF associated variants at ABO, VWF and 2q12 loci primarily affect VWF clearance rates. SUMMARY: Background Previous studies identified common variants at the ABO and VWF loci and unknown variants in a chromosome 2q12 linkage interval that contributed to the variation in plasma von Willebrand factor (VWF) levels. Whereas the association with ABO haplotypes can be explained by differential VWF clearance, little is known about the mechanisms underlying the association with VWF single-nucleotide polymorphisms (SNPs) or with variants in the chromosome 2 linkage interval. VWFpropeptide (VWFpp) and mature VWF are encoded by the VWF gene and secreted at the same rate, but have different plasma half-lives. Therefore, comparison of VWFpp and VWF association signals can be used to assess whether the variants are primarily affecting synthesis/secretion or clearance. Methods We measured plasma VWFpp levels and performed genome-wide linkage and association studies in 3238 young and healthy individuals for whom VWF levels had been analyzed previously. Results and conclusions Common variants in an intergenic region on chromosome 7q11 were associated with VWFpp levels. We found that ABO serotype-specific SNPs were associated with VWFpp levels in the same direction as for VWF, but with a much lower effect size. Neither the association at VWF nor the linkage on chromosome 2 previously reported for VWF was observed for VWFpp. Taken together, these results suggest that the major genetic factors affecting plasma VWF levels, i.e. variants at ABO, VWF and a locus on chromosome 2, operate primarily through their effects on VWF clearance.
Authors: A Y Nossent; V VAN Marion; N H VAN Tilburg; F R Rosendaal; R M Bertina; J A VAN Mourik; H C J Eikenboom Journal: J Thromb Haemost Date: 2006-10-16 Impact factor: 5.824
Authors: Y V Sanders; J G van der Bom; A Isaacs; M H Cnossen; M P M de Maat; B A P Laros-van Gorkom; K Fijnvandraat; K Meijer; C M van Duijn; E P Mauser-Bunschoten; J Eikenboom; F W G Leebeek Journal: J Thromb Haemost Date: 2015-05-09 Impact factor: 5.824
Authors: Karl Desch; Jun Li; Scott Kim; Naomi Laventhal; Kristen Metzger; David Siemieniak; David Ginsburg Journal: Ann Intern Med Date: 2011-09-06 Impact factor: 25.391
Authors: Karl C Desch; Ayse B Ozel; David Siemieniak; Yossi Kalish; Jordan A Shavit; Courtney D Thornburg; Anjali A Sharathkumar; Caitlin P McHugh; Cathy C Laurie; Andrew Crenshaw; Daniel B Mirel; Yoonhee Kim; Cheryl D Cropp; Anne M Molloy; Peadar N Kirke; Joan E Bailey-Wilson; Alexander F Wilson; James L Mills; John M Scott; Lawrence C Brody; Jun Z Li; David Ginsburg Journal: Proc Natl Acad Sci U S A Date: 2012-12-24 Impact factor: 11.205
Authors: Nicholas L Smith; Ming-Huei Chen; Abbas Dehghan; David P Strachan; Saonli Basu; Nicole Soranzo; Caroline Hayward; Igor Rudan; Maria Sabater-Lleal; Joshua C Bis; Moniek P M de Maat; Ann Rumley; Xiaoxiao Kong; Qiong Yang; Frances M K Williams; Veronique Vitart; Harry Campbell; Anders Mälarstig; Kerri L Wiggins; Cornelia M Van Duijn; Wendy L McArdle; James S Pankow; Andrew D Johnson; Angela Silveira; Barbara McKnight; Andre G Uitterlinden; Nena Aleksic; James B Meigs; Annette Peters; Wolfgang Koenig; Mary Cushman; Sekar Kathiresan; Jerome I Rotter; Edwin G Bovill; Albert Hofman; Eric Boerwinkle; Geoffrey H Tofler; John F Peden; Bruce M Psaty; Frank Leebeek; Aaron R Folsom; Martin G Larson; Timothy D Spector; Alan F Wright; James F Wilson; Anders Hamsten; Thomas Lumley; Jacqueline C M Witteman; Weihong Tang; Christopher J O'Donnell Journal: Circulation Date: 2010-03-15 Impact factor: 29.690
Authors: Qianyi Ma; Paula M Jacobi; Brian T Emmer; Colin A Kretz; Ayse Bilge Ozel; Beth McGee; Chava Kimchi-Sarfaty; David Ginsburg; Jun Z Li; Karl C Desch Journal: Blood Adv Date: 2017-06-19
Authors: Ahmad H Mufti; Kenichi Ogiwara; Laura L Swystun; Jeroen C J Eikenboom; Ulrich Budde; Wilma M Hopman; Christer Halldén; Jenny Goudemand; Ian R Peake; Anne C Goodeve; David Lillicrap; Daniel J Hampshire Journal: Blood Adv Date: 2018-07-10
Authors: Erin F Carlton; Walker M McHugh; Kelli McDonough; Julie Sturza; Karl Desch; Timothy T Cornell Journal: Am J Respir Crit Care Med Date: 2020-02-01 Impact factor: 21.405
Authors: Karl C Desch; Ayse B Ozel; Matt Halvorsen; Paula M Jacobi; Krista Golden; Mary Underwood; Marine Germain; David-Alexandre Tregouet; Pieter H Reitsma; Clive Kearon; Lauren Mokry; J Brent Richards; Frances Williams; Jun Z Li; David Goldstein; David Ginsburg Journal: Blood Date: 2020-07-30 Impact factor: 25.476
Authors: Nina Buchtele; Michael Schwameis; James C Gilbert; Christian Schörgenhofer; Bernd Jilma Journal: Thromb Haemost Date: 2018-05-30 Impact factor: 5.249